ScreenerHero

XLOXilio Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · xiliotx.com
9.230USD-1.91%Mkt Cap: 60.73M $P/E: —

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap60.73M $
Enterprise Value-69.00M $
Revenue (TTM)64.09M $
Gross Profit53.30M $
Net Income (TTM)-35.04M $
Revenue/Share9.740 USD
Last Price9.230 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.91
PEG—
EV/EBITDA2.30
EV/Revenue-1.08
P/S0.95
P/B1.19
EPS (TTM)-0.31
EPS (Forward)-0.58
52W Range
6.46844% of range12.74
52W High12.74 USD
52W Low6.468 USD
Profitability
Gross Margin83.16%
Oper. Margin-18.68%
EBITDA Margin-46.86%
Profit Margin-80.05%
ROE-99.33%
ROA-22.65%
Growth
Revenue Growth131.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.99M $
CapEx (TTM)518.00K $
FCF Margin-58.61%
FCF Yield-61.85%
Net Debt-129.74M $
Net Debt/EBITDA4.32
Balance Sheet
Debt/Equity0.20
Current Ratio4.25
Quick Ratio4.15
Book Value/Sh7.785 USD
Cash/Share20.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateMar 16, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.00 USD
Upside (mean)+116.7%
Target Range20.00 USD – 20.00 USD
# Analysts1
Ownership
Shares Out.6.58M
Float3.40M
Insiders25.98%
Institutions50.14%
Short Interest
Short Ratio9.4d
Short % Float7.23%
Short % Out.6.48%
Shares Short425.88K
Short (prev mo.)174.62K
Technical
SMA 508.983 (+2.8%)
SMA 2008.805 (+4.8%)
Beta-0.12
S&P 52W Chg18.16%
Avg Vol (30d)29.52K
Avg Vol (10d)12.79K
Technical Indicators
RSI (14)54.2
MACD0.1089
MACD Signal0.0949
MACD Hist.+0.0140
BB Upper9.591 USD
BB Middle9.096 USD
BB Lower8.601 USD
BB Width10.88%
ATR (14)0.4147 USD
Vol Ratio (20d)0.27x